Telehealth

Belgian biotech MRM Health gets the green light for a Phase 2b trial of MH002, a novel 'living drug' aimed at revolutionizing ulcerative colitis care.

As healthcare costs surge, WTW names Sheila Nordquist its new North America H&B leader. Her mandate: drive growth and navigate an evolving benefits landscape.

With new medical and marketing chiefs, telehealth firm Dutch aims to tackle the vet shortage and redefine pet care for the digital age.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.

Pharma giant Bayer partners with biotech innovator Soufflé to develop a groundbreaking siRNA therapy, aiming to deliver genetic medicine directly to the heart.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

As legacy brand Hamilton Beach heads to a major conference, its high-stakes pivot from kitchen gadgets to health tech will be under the microscope.

Amid industry headwinds, Trinity Health invests $2.9B in community health, pioneering a 'care dividend' to tackle housing, food, and access to care.

A new partnership bypasses PBMs to offer employers cost-effective obesity drugs paired with comprehensive digital care, aiming to reshape health benefits.

From AI-powered diagnostics to non-hallucinogenic psychedelics, 2025's discoveries are redefining mental healthcare and offering new hope.

Teal Health's FDA-authorized Teal Wand is now available in all 50 states, aiming to revolutionize preventive care for millions of overdue women.

A new tri-specific antibody, IM1240, safely hits cancer cells at massive doses in preclinical studies, potentially solving a key toxicity problem in immunotherapy.

With a device that calms deadly 'cytokine storms,' SeaStar Medical targets vast new markets, but can the small company deliver on its huge promises?

Aerospace veteran John Slattery brings his expertise to Orbis International, aiming to elevate the mission of its unique Flying Eye Hospital.

A routine prenatal screen can now detect a virus that causes birth defects, offering a path to prevention and sparking calls to change medical guidelines.

LifeVantage heads to the ICR Conference to woo investors. Can its cellular health science overcome market headwinds and a volatile direct selling landscape?

Transcarent's WayFinding 2.0 moves beyond chat, using 'agentic AI' to schedule appointments, create health plans, and actively manage your care.

With a hot obesity pipeline and a key neurology asset, Nxera Pharma's J.P. Morgan talk is a crucial test of its plan for global leadership.

RxSight will showcase its unique post-surgery adjustable lens at J.P. Morgan, facing investor questions on growth in a competitive ophthalmology market.

With a blockbuster 2025 in the books, Boston Scientific's leadership faces intense scrutiny at upcoming investor events to prove its growth is sustainable.